arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a Novel anti-CD70 Antibody, in Cancer Patients

arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study.